ViroStatics is a biopharmaceutical company dedicated to the discovery and development of small molecule drugs for the treatment of cancer and viral infections. The Company’s research and development program is focused on novel, highly selective, host cell kinase targeted inhibitors. ViroStatics’ robust pipeline is led by VS2-370, a kinase inhibitor that has a differentiated efficacy and safety profile compared to competitors based on its unique enzymatic selectivity. VS2-370 targets CDK4, CDK6 and CDK9 in a specific and synergistic fashion.
To date, VS2-370 has demonstrated potent activity in preclinical studies against aggressive cancers with high unmet medical need, including pancreatic cancer, highly malignant lymphomas and acute leukemias, lung cancer and breast cancer. VS2-370 also has the potential to treat HIV by targeting host cell kinase dependent reservoir sustaining pathways. In addition to back-up compounds for oncology and HIV, ViroStatics has a pipeline of novel candidates that demonstrated potent activity in preclinical studies against varicella zoster virus, hepatitis B virus and Epstein-Barr virus.